Rheumatology community responds to FDA approval of Inflectra (Infliximab-dyyb), a Biosimilar to Remicade

The ACR has issued an official statement regarding the FDA’s approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail